NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.38 -0.02 (-1.43 %)
(As of 04/26/2019 12:43 PM ET)
Previous Close$1.40
Today's Range$1.35 - $1.4272
52-Week Range$0.20 - $2.96
Volume130,057 shs
Average Volume901,424 shs
Market Capitalization$92.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66
Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240,000.00
Book Value($0.45) per share

Profitability

Net Income$-26,610,000.00

Miscellaneous

Employees29
Market Cap$92.92 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. View Sunesis Pharmaceuticals' Earnings History.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Sunesis Pharmaceuticals.

What price target have analysts set for SNSS?

3 equities research analysts have issued 12-month target prices for Sunesis Pharmaceuticals' shares. Their forecasts range from $0.50 to $6.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.25 in the next year. This suggests a possible upside of 137.2% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.

What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals.

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

News articles about SNSS stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), NVIDIA (NVDA), QUALCOMM (QCOM), Exelixis (EXEL), Micron Technology (MU), Conatus Pharmaceuticals (CNAT), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $1.37.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $92.58 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is http://www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  686
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel